ArticleFood science & nutrition2026
Effects of Synbiotic Supplementation on Bone Turnover Markers in Kidney Transplant Recipients: A Randomized Controlled Trial.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone disorders are common in kidney transplant (KT) recipients. This research explores the impact of synbiotic supplementation on markers related to bone turnover in these patients. In a randomized controlled trial, 46 KT recipients were allocated at random to either a synbiotic group or a placebo group. Those in the synbiotic group received two capsules daily for a duration of 12 weeks, while the placebo group was given an equivalent placebo. The study measured several bone resorption markers, including C-telopeptide and receptor activator of nuclear factor kappa B ligand (RANKL), as well as serum levels of the bone formation marker osteocalcin and the bone resorption inhibitor osteoprotegerin. The findings revealed that serum levels of C-telopeptide were significantly lower in the synbiotic group compared to the placebo group (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.